Physician profile
Jennifer E Smith
NPI 1215919170
$2,548.01
in general payments reported to CMS, 2019-2025
38 companies · $903 in 2025
The $903 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $132 · 2021: $13.84 · 2022: $25.97 · 2023: $587 · 2024: $552 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $355.91 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $210.61 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $205.35 | 2019-2024 | Prolia, Evenity, Otezla |
| Abbvie INC. | $202.85 | 2023-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $197.05 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $166.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $161.14 | 2023-2025 | |
| Corcept Therapeutics | $97.41 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $89.07 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.18 | 2019-2025 | Jardiance, Glyxambi, Tradjenta |
| Phathom Pharmaceuticals, INC. | $70.21 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $62.38 | 2019-2023 | Veozah, Myrbetriq |
| Sanofi Pasteur INC. | $59.93 | 2020-2023 | |
| Insulet Corporation | $55.74 | 2025 | Omnipod |
| Hologic Sales and Service, LLC | $53.22 | 2023-2025 | Thinprep 2000 Processor, Aptima |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.